# OnCo record paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024" ;
  schema:name "Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma"@en ;
  schema:description "In osteosarcoma, a personalised blood test for leftover cancer after surgery predicted who would relapse, sometimes months before scans."@en ;
  schema:url <https://onco.cc/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.eclinm.2024.102697>, <https://pubmed.ncbi.nlm.nih.gov/39022798/> ;
  schema:sameAs <https://doi.org/10.1016/j.eclinm.2024.102697> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Fu Y, Xu Y, Liu W, et al." ;
  onco:cancers <https://onco.cc/cancers/osteosarcoma/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/orimiracle-s/> ;
  onco:companies <https://onco.cc/companies/origimed/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> .